(Q46066342)

19 December 2017

title

Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes (English)

1 reference

19 December 2017

0 references

0 references

1 reference

M Velojic-Golubovic

1

1 reference

19 December 2017

D Mikic

2

1 reference

19 December 2017

M Pesic

3

1 reference

19 December 2017

D Dimic

4

1 reference

19 December 2017

S Radenkovic

5

1 reference

19 December 2017

S Antic

6

1 reference

19 December 2017

publication date

1 January 2009

1 reference

19 December 2017

Journal of Endocrinological Investigation

published in

1 reference

19 December 2017

volume

32

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

23-27

1 reference

19 December 2017

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Premixed insulin treatment for type 2 diabetes: analogue or human?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Injection-meal interval: recommendations of diabetologists and how patients handle it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Monomeric insulins and their experimental and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Obesity medications and the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345673

Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

21 January 2018

1 reference

12 December 2020

Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits

1 reference

12 December 2020

Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart

1 reference

12 December 2020

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345673

1 reference

19 December 2017

1 reference

19 December 2017